Safety and Efficacy of Tigecycline to Treat Multidrug-resistant Infections in Pediatrics: An Evidence Synthesis.

导出原文传递

翻译打印收藏纠错

第一作者： Mike,Sharland

第一单位： From the Paediatric Infectious Diseases Research Group, St. George's, University of London, London, United Kingdom.

作者： Mike,Sharland ^[1] ; Keith A,Rodvold ^[2] ; Hal R,Tucker ^[3] ; Nathalie,Baillon-Plot ^[4] ; Margaret,Tawadrous ^[5] ; M Anne,Hickman ^[6] ; Susan,Raber ^[7] ; Joan M,Korth-Bradley ^[8] ; Humberto,Díaz-Ponce ^[9] ; Michele,Wible ^[10]

作者单位： From the Paediatric Infectious Diseases Research Group, St. George's, University of London, London, United Kingdom. ^[1] Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois. ^[2] Established Products Business Unit, Pfizer Inc., Collegeville, Pennsylvania. ^[3] Antibacterials Europe, Pfizer PFE, Paris, France. ^[4] Clinical Research and Development, Pfizer Inc., Groton, Connecticut. ^[5] Worldwide Safety and Regulatory, Pfizer Inc., Groton, Connecticut. ^[6] Clinical Pharmacology, Pfizer Essential Health, Pfizer Inc., La Jolla, California. ^[7] Clinical Pharmacology, Pfizer Inc., Collegeville, Pennsylvania. ^[8] LATAM Anti-infectives, Pfizer México, Mexico City, Mexico (affiliation at the time when the study was conducted). ^[9] Biostatistics, Pfizer Inc., Collegeville, Pennsylvania. ^[10]